TRDA — Entrada Therapeutics Share News
0.000.00%
Last trade - 00:00- $171.71m
- -$51.29m
- $25.42m
Entrada Therapeutics Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: Entrada Therapeutics - On Oct 26 Co, Vertex Pharmaceuticals Entered Amendment No. 1 To Strategic Collaboration & License Agreement, Dated Dec 7, 2022
Brief: Entrada Therapeutics Doses First Participant In Phase 1 Trial Of Entr-601-44 In Treating Duchenne Muscular Dystrophy
Brief: Entrada Therapeutics, Inc. Q2 EPS USD -0.78
Brief: Entrada Therapeutics Receives Authorization In United Kingdom To Initiate Phase 1 Clinical Trial Of ENTR-601-44 For Potential Treatment Of Duchenne Muscular Dystrophy
Brief: Entrada Therapeutics Reports Q1 2023 Financial Results
Brief: Entrada Therapeutics Says Expanded Size Of Board From Seven To Eight Directors
Brief: Entrada Therapeutics Appoints Bernhardt Zeiher To Its Board Of Directors
Brief: Entrada Closes Agreement With Vertex For Endosomal Escape Vehicle-Therapeutics for Myotonic Dystrophy Type 1 (DM1)
Brief: Entrada Therapeutics Announces Clinical Candidate For Treatment Of Duchenne Muscular Dystrophy
U.S. STOCKS ON THE MOVE-Tesla, Athenex Inc, Entrada Therapeutics
U.S. STOCKS ON THE MOVE-Tesla, Netflix, Entrada Therapeutics, Gilead Sciences
Entrada eyes worst day ever after clinical hold on DMD therapy trial application
Entrada Therapeutics slumps as FDA puts DMD therapy trial application on hold
Brief: Entrada Therapeutics Announces Clinical Hold On Ind Application For Entr-601-44 In Duchenne Muscular Dystrophy
U.S. STOCKS ON THE MOVE-Regenxbio, Hello Group, copper miners
U.S. STOCKS ON THE MOVE-Express, Hershey, Entrada Therapeutics
Entrada Therapeutics up on muscle wasting disorder therapy deal
Brief: Vertex And Entrada Therapeutics Establish Collaboration To Discover And Develop Endosomal Escape Vehicle Therapeutics For Myotonic Dystrophy Type 1